Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis.
adjuvant treatment
endometrial cancer
molecular profile
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
revised:
24
02
2022
received:
29
11
2021
accepted:
28
02
2022
pubmed:
27
5
2022
medline:
12
7
2022
entrez:
26
5
2022
Statut:
ppublish
Résumé
The integration of molecular features with clinicopathological findings in endometrial cancer classification seems to be able to significantly refine risk assessment. Nevertheless, clinical management remains challenging, and different therapeutic options are available for each class. Further prognostic characterization of the subgroups within each risk class could be helpful in the decision-making process. This study evaluated the role of the 2020 European Society of Gynaecological Oncology (ESGO)/European Society for Radiotherapy and Oncology (ESTRO)/European Society of Pathology (ESP) risk assessment system and the three prognostic profiles adopted in the PORTEC-4a trial in predicting disease-free and overall survival in a retrospective study cohort of patients with early-stage endometrial cancer. Patients were selected according to a 1:2 propensity score matching analysis. Moreover, the sequencing of 29 genes was undertaken for tumor samples. The study included 137 patients. No differences in disease-free or overall survival at 5 years were observed among the 2020 ESGO/ESTRO/ESP risk classes without molecular features (p = .766 and p = .176, respectively). Once molecular features were integrated, the probability of overall survival was significantly different (p = .011). When the three prognostic profiles were applied, the probability of recurrence had a p value of .097, and significant differences were observed in overall survival (p = .004). Among patients experiencing recurrence, 17.6% showed mutations in BRCA1/2, RAD50, BRIP1, and XRCC2, whereas 22.5% had PD-L1-positive expression and an MUTYH mutation. Further stratification within each risk class according to the most relevant prognostic features could better define the prognosis of patients with early-stage endometrial cancer. Nearly half of the patients who experienced recurrence showed a targetable molecular alteration for which dedicated trials should be encouraged.
Sections du résumé
BACKGROUND
The integration of molecular features with clinicopathological findings in endometrial cancer classification seems to be able to significantly refine risk assessment. Nevertheless, clinical management remains challenging, and different therapeutic options are available for each class. Further prognostic characterization of the subgroups within each risk class could be helpful in the decision-making process.
METHODS
This study evaluated the role of the 2020 European Society of Gynaecological Oncology (ESGO)/European Society for Radiotherapy and Oncology (ESTRO)/European Society of Pathology (ESP) risk assessment system and the three prognostic profiles adopted in the PORTEC-4a trial in predicting disease-free and overall survival in a retrospective study cohort of patients with early-stage endometrial cancer. Patients were selected according to a 1:2 propensity score matching analysis. Moreover, the sequencing of 29 genes was undertaken for tumor samples.
RESULTS
The study included 137 patients. No differences in disease-free or overall survival at 5 years were observed among the 2020 ESGO/ESTRO/ESP risk classes without molecular features (p = .766 and p = .176, respectively). Once molecular features were integrated, the probability of overall survival was significantly different (p = .011). When the three prognostic profiles were applied, the probability of recurrence had a p value of .097, and significant differences were observed in overall survival (p = .004). Among patients experiencing recurrence, 17.6% showed mutations in BRCA1/2, RAD50, BRIP1, and XRCC2, whereas 22.5% had PD-L1-positive expression and an MUTYH mutation.
CONCLUSIONS
Further stratification within each risk class according to the most relevant prognostic features could better define the prognosis of patients with early-stage endometrial cancer. Nearly half of the patients who experienced recurrence showed a targetable molecular alteration for which dedicated trials should be encouraged.
Identifiants
pubmed: 35617463
doi: 10.1002/cncr.34331
pmc: PMC9541547
doi:
Substances chimiques
DNA-Binding Proteins
0
XRCC2 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2898-2907Informations de copyright
© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Biometrics. 1983 Jun;39(2):499-503
pubmed: 6354290
Mod Pathol. 2015 Jun;28(6):836-44
pubmed: 25720322
Ann Oncol. 2017 Jan 1;28(1):96-102
pubmed: 27742654
Cancer Chemother Rep. 1966 Mar;50(3):163-70
pubmed: 5910392
Br J Cancer. 2018 Aug;119(4):480-486
pubmed: 30050154
Ann Oncol. 2018 May 1;29(5):1180-1188
pubmed: 29432521
Clin Cancer Res. 2016 Aug 15;22(16):4215-24
pubmed: 27006490
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Gynecol Oncol. 2020 Apr;157(1):245-251
pubmed: 31980219
J Clin Oncol. 2020 Oct 10;38(29):3388-3397
pubmed: 32749941
Hum Pathol. 2021 May;111:98-109
pubmed: 33662372
Exp Ther Med. 2017 Sep;14(3):2683-2688
pubmed: 28962212
Br J Cancer. 2015 Jul 14;113(2):299-310
pubmed: 26172027
Int J Gynecol Cancer. 2020 Dec;30(12):2002-2007
pubmed: 33046573
Cancer. 2017 Mar 1;123(5):802-813
pubmed: 28061006
Gynecol Oncol. 2021 Aug;162(2):394-400
pubmed: 34127276
Am J Surg Pathol. 2017 Feb;41(2):245-252
pubmed: 28079598